Press "Enter" to skip to content

FDA Grants Orphan Drug Status to BXCL701 as Potential AML Treatment – Immuno-Oncology News

admin 0

FDA Grants Orphan Drug Status to BXCL701 as Potential AML Treatment  Immuno-Oncology News

The FDA has granted orphan drug status to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies, for the treatment of AML.

“pancreatic cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *